These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19151534)

  • 1. Drug discovery for overcoming chronic kidney disease (CKD): the endothelin ET B receptor/nitric oxide system functions as a protective factor in CKD.
    Ohkita M; Takaoka M; Matsumura Y
    J Pharmacol Sci; 2009 Jan; 109(1):7-13. PubMed ID: 19151534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.
    Schneider MP; Boesen EI; Pollock DM
    Annu Rev Pharmacol Toxicol; 2007; 47():731-59. PubMed ID: 17002597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():50-67. PubMed ID: 19335747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.
    Tullos NA; Stewart NJ; Davidovich R; Chade AR
    Nephrol Dial Transplant; 2015 Apr; 30(4):584-93. PubMed ID: 25438341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
    Goddard J; Johnston NR; Hand MF; Cumming AD; Rabelink TJ; Rankin AJ; Webb DJ
    Circulation; 2004 Mar; 109(9):1186-93. PubMed ID: 14981006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
    Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension.
    Opocenský M; Kramer HJ; Bäcker A; Vernerová Z; Eis V; Cervenka L; Certíková Chábová V; Tesar V; Vanecková I
    Hypertension; 2006 Nov; 48(5):965-71. PubMed ID: 17015777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiological roles of endothelin receptors in cardiovascular diseases.
    Ohkita M; Tawa M; Kitada K; Matsumura Y
    J Pharmacol Sci; 2012; 119(4):302-13. PubMed ID: 22863667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
    Ruschitzka F; Quaschning T; Noll G; deGottardi A; Rossier MF; Enseleit F; Hürlimann D; Lüscher TF; Shaw SG
    Circulation; 2001 Jun; 103(25):3129-35. PubMed ID: 11425780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrarenal ETB plays a significant role in controlling cardiovascular responses to high dietary sodium in rats.
    Ohkita M; Wang Y; Nguyen ND; Tsai YH; Williams SC; Wiseman RC; Killen PD; Li S; Yanagisawa M; Gariepy CE
    Hypertension; 2005 May; 45(5):940-6. PubMed ID: 15809364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
    Zager RA; Johnson AC; Andress D; Becker K
    Kidney Int; 2013 Oct; 84(4):703-12. PubMed ID: 23698233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system blockade alone or combined with ET
    Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
    Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
    Rothermund L; Kossmehl P; Neumayer HH; Paul M; Kreutz R
    J Hypertens; 2003 Dec; 21(12):2389-97. PubMed ID: 14654760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts.
    Yamamoto S; Matsumoto N; Kanazawa M; Fujita M; Takaoka M; Gariepy CE; Yanagisawa M; Matsumura Y
    Circulation; 2005 Jan; 111(3):302-9. PubMed ID: 15642760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual constrictor and dilator actions of ET(B) receptors in the rat renal microcirculation: interactions with ET(A) receptors.
    Just A; Olson AJ; Arendshorst WJ
    Am J Physiol Renal Physiol; 2004 Apr; 286(4):F660-8. PubMed ID: 14678950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA(2) mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats.
    Ajayi AA; Ogungbade GO; Hercule HC; Oyekan AO; Mutembei L
    Diabetes Res Clin Pract; 2004 Mar; 63(3):155-69. PubMed ID: 14757287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of endothelin ET(A) and ET(B) receptor subtypes in the regulation of intrarenal blood flow and oxygen tension in rats.
    Nitescu N; Grimberg E; Herlitz H; Guron G
    Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1227-32. PubMed ID: 18518881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.
    Dhaun N; Ferro CJ; Davenport AP; Haynes WG; Goddard J; Webb DJ
    Nephrol Dial Transplant; 2007 Nov; 22(11):3228-34. PubMed ID: 17556408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effects of ET(A) receptor antagonists therapy in experimental non-diabetic chronic kidney disease: Is there still hope for the future?
    Vaněčková I; Hojná S; Kadlecová M; Vernerová Z; Kopkan L; Červenka L; Zicha J
    Physiol Res; 2018 Jun; 67(Suppl 1):S55-S67. PubMed ID: 29947528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective antagonism of endothelin ET(A) or ET(B) receptor in renal hemodynamics and function of deoxycorticosterone acetate-salt-induced hypertensive rats.
    Matsumura Y; Taira S; Kitano R; Hashimoto N; Kuro T
    Biol Pharm Bull; 1999 Aug; 22(8):858-62. PubMed ID: 10480326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.